Literature DB >> 15919768

Pharmacodynamics of antibiotics with respect to bacterial killing of and release of lipoteichoic acid by Streptococcus pneumoniae.

Herman Mattie1, Kristin Stuertz, Roland Nau, Jaap T van Dissel.   

Abstract

OBJECTIVES: There are marked differences in the amount of immunoreactive components such as lipoteichoic acid (LTA) released from Gram-positive bacteria following exposure to different antibiotics. Little is known about the kinetics and amount of release of such components in relation to bacterial killing.
METHODS: Bacterial killing and LTA release from Streptococcus pneumoniae type 3 during exposure to ceftriaxone, meropenem, rifampicin, rifabutin, quinupristin/dalfopristin, and trovafloxacin in tryptic soy broth were quantified microbiologically and by ELISA, respectively. We applied a mathematical model to characterize quantitatively the amount of lipoteichoic acid released and the statistical moments of this release.
RESULTS: The model approach revealed that (i) the lag time to release of LTA was very similar for individually killed bacterial cells (approximately 120 min), whatever the killing mechanism effected by the antibiotic, and (ii) the amount of LTA released per killed bacterial cell, a value that we regard as an indicator of the relation between antibacterial efficacy and possible adverse immunostimulatory effects due to release of cell wall components, differs markedly between antibiotics, even at antibiotic concentrations inducing equal killing. Rifamycins were most effective in killing S. pneumoniae while causing the least LTA release per killed bacterial cell; the amount released was about one-half that by quinupristin-dalfopristin and trovafloxacin, and one-quarter that by ceftriaxone and meropenem.
CONCLUSIONS: In the evaluation of antibacterial drugs, the present model provides useful information on the whole process of bacterial killing and release of immunoreactive components from the bacterial cell wall.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15919768     DOI: 10.1093/jac/dki176

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

Review 1.  Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Allan R Tunkel; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

2.  Clinical characteristics and outcomes of peritoneal dialysis-related peritonitis with different trends of change in effluent white cell count: a longitudinal study.

Authors:  Rong Xu; Yuan Chen; Suping Luo; Ying Xu; Bo Zheng; Yingdong Zheng; Jie Dong
Journal:  Perit Dial Int       Date:  2013-06-03       Impact factor: 1.756

3.  Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.

Authors:  Denis Grandgirard; Christian Schürch; Philippe Cottagnoud; Stephen L Leib
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

Review 4.  Dexamethasone in adults with community-acquired bacterial meningitis.

Authors:  Diederik van de Beek; Jan de Gans
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Platelet-activating factor-acetylhydrolase can monodeacylate and inactivate lipoteichoic acid.

Authors:  Ho Seong Seo; Je Hak Kim; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2006-04

6.  Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial.

Authors:  Geert H Groeneveld; Tanny J van der Reyden; Simone A Joosten; Hester J Bootsma; Christa M Cobbaert; Jutte J C de Vries; Ed J Kuijper; Jaap T van Dissel
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

7.  The human milk protein-lipid complex HAMLET sensitizes bacterial pathogens to traditional antimicrobial agents.

Authors:  Laura R Marks; Emily A Clementi; Anders P Hakansson
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.